Interested in finding a better way to develop drugs to treat amyotrophic lateral sclerosis (ALS), Northeastern researcher ...

UM researchers have developed a deep learning model to predict compound protein interactions. GraphBAN is an inductive ...

ProFuse's novel technology addresses the growing need to preserve muscle in the face of aging and the popularity of ...

Schrödinger’s stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug ...

AMPLY, the company behind the proprietary AMPLYfolioAI platform, is accelerating the discovery of new medicines for complex ...

PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced ...

Elix Inc. has entered into a drug discovery collaboration with Prism Biolab Co. Ltd. to accelerate AI-driven drug discovery for challenging protein-protein interaction targets. The partnership will ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that ...

Identifying a key protein’s role could improve the common mental health medications and point to new treatments for inflammation-related diseases, VCU medicinal chemist Youzhong Guo says.

Expiring patents can be a catalyst for M&A in the life sciences industry as pharmaceutical and biotechnology companies seek ...

Choosing between plate reader-based assays and mass spectrometry solutions is a key decision for scientists when evaluating ...

With the advent of artificial intelligence (AI), predictive medicine is becoming an important part of healthcare, especially ...